ProfessorPaulKellam

Faculty of Medicine, Department of Infectious Disease

Professor of Virus Genomics

Contact

Location

460Wright Fleming WingSt Mary's Campus

Summary

Paul Kellam is the Professor of Virus Genomics at Imperial College London and Vice President of infectious diseases & vaccines at Kymab Ltd, UK. He has published over 200 primary research papers, reviews, book chapters and patents. Paul Is a Fellow of the American Academy of Microbiology and Council Member of the UK Microbiology Society.

Paul’s scientific career has spanned the pharmaceutical industry, at the Wellcome Foundation Ltd and Kymab Ltd and academia, where Paul was the Virus Genomics lead at the Wellcome Trust Sanger Institute and a Professor of Virology at UCL.

Paul’s research has identified how HIV develops resistance to antiviral drugs and has identified the first influenza disease severity gene in people hospitalised with influenza virus. His laboratory produced the virus genome analysis of the Middle East Respiratory Syndrome Coronavirus (MERS CoV) outbreaks working with the Department of Health in Saudi Arabia, showing that the transmission pattern of the virus was consistent with multiple transfer events from an animal reservoir and contributing to the identification of camels as the animal reservoir. His laboratory contributed to the international Ebola virus genome analysis to help the WHO control the outbreak and to show the factors influencing virus transmission.

In 2016 Paul became the Professor of Virus Genomics at Imperial College London and the Vice President of Infectious Diseases & Vaccines at Kymab Ltd. The Imperial College laboratory is continuing its research theme of investigating virus and host genetic variation during infection. At Kymab Pauls’ work is focusing on using the Kymouse to develop therapeutic antibody treatments of infectious diseases and to further advance vaccine research.

Publications

Journals

Thai E, Murugan R, Binter Š, et al.Thai E, Murugan R, Binter Š, Burn Aschner C, Prieto K, Kassardjian A, Obraztsova AS, Kang RW, Flores-Garcia Y, Mathis-Torres S, Li K, Horn GQ, Huntwork RHC, Bolscher JM, de Bruijni MHC, Sauerwein R, Dennison SM, Tomaras GD, Zavala F, Kellam P, Wardemann H, Julien J-P close, 2023, Molecular determinants of cross-reactivity and potency by VH3-33 antibodies against the Plasmodium falciparum circumsporozoite protein, Cell Reports, Vol:42, ISSN:2211-1247

Abdullahi A, Kida IM, Maina UA, et al.Abdullahi A, Kida IM, Maina UA, Ibrahim AH, Mshelia J, Wisso H, Adamu A, Onyemata JE, Edun M, Yusuph H, Aliyu SH, Charurat M, Abimiku A, Abeler-Dorner L, Fraser C, Bonsall D, PANGEA C, Kemp SA, Gupta RK close, 2023, Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort, Journal of Antimicrobial Chemotherapy, Vol:78, ISSN:0305-7453, Pages:2000-2007

Kugathasan R, Sukhova K, Moshe M, et al.Kugathasan R, Sukhova K, Moshe M, Kellam P, Barclay W close, 2023, Deep mutagenesis scanning using whole trimeric SARS-CoV-2 spike highlights the importance of NTD-RBD interactions in determining spike phenotype, Plos Pathogens, Vol:19, ISSN:1553-7366

Ludwig J, Scally SW, Costa G, et al.Ludwig J, Scally SW, Costa G, Hoffmann S, Murugan R, Lossin J, Prieto K, Obraztsova A, Lobeto N, Franke-Fayard B, Janse CJ, Lebas C, Collin N, Binter S, Kellam P, Levashina EA, Wardemann H, Julien J-P close, 2023, Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model, Npj Vaccines, Vol:8, ISSN:2059-0105

Higham SL, Baker S, Flight KE, et al.Higham SL, Baker S, Flight KE, Krishna A, Kellam P, Reece ST, Tregoning JS close, 2023, Intranasal immunisation with Outer Membrane Vesicles (OMV) protects against airway colonisation and systemic infection with Acinetobacter baumannii., Journal of Infection, Vol:86, ISSN:0163-4453, Pages:563-573

More Publications